PLSE — Pulse Biosciences Income Statement
0.000.00%
Last trade - 00:00- $1.20bn
- $1.09bn
- 30
- 18
- 78
- 37
Annual income statement for Pulse Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.42 | 0.7 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | -0.55 | -11.2 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 50 | 64.4 | 58.8 | 43.6 | 56.3 |
| Operating Profit | -50 | -63 | -58.1 | -43.6 | -56.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -49.9 | -63.7 | -58.5 | -42.2 | -53.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -49.9 | -63.7 | -58.5 | -42.2 | -53.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -49.9 | -63.7 | -58.5 | -42.2 | -53.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.9 | -63.7 | -58.5 | -42.2 | -53.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.14 | -2.28 | -1.7 | -0.877 | -0.885 |